SRZN Surrozen Inc

$SRZN easy money SZN-8141 has never been tested in humans. SRZN has no human efficacy data for its lead drug. First human data aren't expected until H2 2027. Today's catalyst was Merck's clinical success, not SRZN's. Merck has effectively beaten SRZN to human proof of the Wnt concept. SRZN burns cash and has significant potential dilution through its ATM, PIPE and warrants. At ~$30, investors are paying heavily today for clinical success that SRZN itself has yet to demonstrate.

$SRZN company has less than $100 million in cash with only phase 1 trials. They'll have to issue new shares soon to keep funding these trials. No revenue until 2027.

$SRZN they are stuck here with selling pressure, no one is buying. They have increased the spread, wont hold

$SRZN if you think shorting is a good idea here you should keep in mind that a buyout around IND clearance is a real possibility. TCG is preparing the company for an exit since Q4 2025 so don't be surprised if it happens.

$SRZN 200 million shelf offering means, more shares will be added than the company already having....we ll see it in a single digit

$SRZN stocks pumped with no news, is oftn by a single sponsored pump and results in an offering. This consolidation helps them get rid of their shares and create exit liquidity before dumping otherwise who is buying here at 2 years high price. Market makers complicit in this act

$SRZN when they start utilizing the 50M ATM ? No rev, he fatigue cash flow and not even close to have an approved product

$SRZN Phase ONE Trial (for only nine participants) estimated to complete end of August 2027. Will receive data second half of next year.

$SRZN Asking for a friend. How much did TD Cowen help raise the money for the company today. AT how many shares and at what price?

$SRZN hc Wainwright loves to give ridiculous evaluations and then participate in the offering. Super corrupt

$SRZN Company tapping that ATM like a leaky faucet today. See all those double digit share trades? Sneaky.

$SRZN Big win if you followed my call couple days ago Congrats fallowers Keep following for more swing idea 💡

$SRZN what's the news? absolutely no news. Incredible that people buy stock in companies with bad fundamentals like this one.

$SRZN TCG not selling into the Brunello pump could mean that they are not allowed to sell because of insider information. With second tranche dilution at $11.6 which will happen soon it could make sense to sell but seems like they did not.

$SRZN Please hold the price so we can participate in the offering. I would slowly accumulate the short position and then buy back when volume come after the offering.

$SRZN this is not a day trade. Merck now has to decide if they want to settle their patent battle with Surrozen with a license or buy the whole company. Roche, Regeneron and BI have to decide if they want to buy Surrozen before somebody else is doing it.

$SRZN Options trading for this stock started on Monday, tomm is the close date hence its being pumped, once the options traders get out today the stock will crash at opening bell

$SRZN — Surrozen is taking an interesting approach to diabetic macular edema with SZN-8141. Instead of relying solely on VEGF inhibition, the drug combines VEGF inhibition with activation of the Wnt pathway, potentially addressing vascular damage through two mechanisms. The IND has been submitted, making clinical clearance and first-patient dosing the next milestones I’m interested in.

$SRZN — Surrozen recently filed the IND for SZN-8141 in diabetic macular edema. The drug combines Wnt-pathway activation with VEGF inhibition, potentially attacking the disease from two different directions. Subject to clearance, the company wants to begin its first clinical study by year-end.

$SRZN — Surrozen just submitted an IND for SZN-8141, an experimental treatment for diabetic macular edema that combines Wnt-pathway activation with VEGF inhibition. The company is targeting the start of its first clinical study by year-end, subject to clearance. Moving from preclinical work into humans is an important inflection point for a biotech this size.